نتایج جستجو برای: peginterferon alfa
تعداد نتایج: 19203 فیلتر نتایج به سال:
Chronic hepatitis B is a major global health problem. Fortunately there are currently a number of agents licensed in most countries to treat chronic hepatitis B, including the oral nucleos(t)ide agents lamivudine, adefovir, entecavir, telbivudine, and tenofovir, and the immune modulators interferon alfa-2b and peginterferon alfa-2a. Large clinical trials have shown potent suppression of viral r...
BACKGROUND In patients with chronic hepatitis C who do not have a response to antiviral treatment, the disease may progress to cirrhosis, liver failure, hepatocellular carcinoma, and death. Whether long-term antiviral therapy can prevent progressive liver disease in such patients remains uncertain. METHODS We conducted a randomized, controlled trial of peginterferon alfa-2a at a dosage of 90 ...
BACKGROUND In patients with chronic infection with hepatitis C virus (HCV) genotype 1 who do not have a sustained response to therapy with peginterferon-ribavirin, outcomes after retreatment are suboptimal. Boceprevir, a protease inhibitor that binds to the HCV nonstructural 3 (NS3) active site, has been suggested as an additional treatment. METHODS To assess the effect of the combination of ...
BACKGROUND The standard treatment for hepatitis C virus (HCV) infection is interferon, which is administered subcutaneously and can have troublesome side effects. We evaluated sofosbuvir, an oral nucleotide inhibitor of HCV polymerase, in interferon-sparing and interferon-free regimens for the treatment of HCV infection. METHODS We provided open-label treatment to eight groups of patients. A ...
T he combination of interferons and ribavirin is the cornerstone of treatment for hepatitis C virus (HCV) infection. 1,2 Close monitoring is necessary for patients on therapy for HCV since 10–15% of patients will discontinue therapy because of adverse effects such as neutropenia, anemia, thrombocytopenia, and suicidal ideation. 1-3 Recommendations for HCV treatment were developed at the Nationa...
BACKGROUND & AIMS The Hepatitis C Antiviral Long-term Treatment Against Cirrhosis (HALT-C) trial demonstrated that low-dose peginterferon maintenance therapy was ineffective in preventing clinical outcomes in patients with chronic hepatitis C, advanced fibrosis, and failure to achieve a sustained virologic response during lead-in phase treatment with standard dose peginterferon/ribavirin. This ...
The highest response rates to antiviral therapy for the treatment of chronic hepatitis C have been achieved using the combination of peginterferon and ribavirin. Recently completed controlled trials have reported rates of sustained virological response (SVR) between 50% and 60% in patients treated with higher doses of peginterferon and ribavirin, which was 5% to 10% higher with standard doses o...
نمودار تعداد نتایج جستجو در هر سال
با کلیک روی نمودار نتایج را به سال انتشار فیلتر کنید